[{"data":1,"prerenderedAt":235},["ShallowReactive",2],{"drug-ivabradine":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":21,"regimens":53,"contraindications":119,"warnings":129,"renal":130,"monitoring":131,"interactions":132,"review":133,"examples":136,"atc":152,"iran":154,"links":170,"populations":187,"usApproval":230},"ivabradine",1,{"fa":7,"en":8},"ایوابرادین","Ivabradine","cardiovascular",{"fa":11,"en":12},"مهارکننده کانال If گره سینوسی","Sinus node If-channel inhibitor",[14],{"name":15,"market":16},"Corlanor","US",[18,19,20,7],"corlanor","procoralan","کورلانور",[22,36,45],{"id":23,"form":24,"route":25,"label":26,"concentration":27,"markets":31,"refs":32},"tab-5","tablet","oral","5 mg tablet (scored)",{"amount":28,"unit":29,"perUnit":24,"scored":30},5,"mg",true,[16],[33],{"source":34,"section":35},"fda-corlanor","3",{"id":37,"form":24,"route":25,"label":38,"concentration":39,"markets":42,"refs":43},"tab-7-5","7.5 mg tablet",{"amount":40,"unit":29,"perUnit":24,"scored":41},7.5,false,[16],[44],{"source":34,"section":35},{"id":46,"form":47,"route":25,"label":48,"concentration":49,"markets":50,"refs":51},"sol-1","solution","5 mg\u002F5 mL oral solution",{"amount":28,"unit":29,"perVolumeMl":28},[16],[52],{"source":34,"section":35},[54,80,105],{"id":55,"disease":56,"label":57,"population":60,"type":64,"unit":29,"dose":65,"refs":67,"limits":70,"notes":73},"adult","heart-failure",{"fa":58,"en":59},"نارسایی قلب بزرگسال — شروع ۵ mg دو بار در روز با غذا","Adult heart failure — start 5 mg twice daily with food",{"minAge":61},{"value":62,"unit":63},18,"year","fixed",{"perDose":28,"dosesPerDay":66},2,[68],{"source":34,"section":69},"2.1",{"maxPerDose":40,"refs":71},[72],{"source":34,"section":69},[74],{"text":75,"refs":78},{"fa":76,"en":77},"پس از ۲ هفته بر اساس ضربان استراحت (هدف ۵۰ تا ۶۰): بالای ۶۰ → ۲٫۵ mg بیشتر تا حداکثر ۷٫۵ mg دو بار؛ زیر ۵۰ یا برادی‌کاردی → ۲٫۵ mg کمتر. در اختلال هدایت از ۲٫۵ mg دو بار شروع.","After 2 weeks adjust to resting HR 50–60: >60 → +2.5 mg up to 7.5 mg twice daily; \u003C50 or bradycardia → −2.5 mg. Start 2.5 mg twice daily with conduction defects.",[79],{"source":34,"section":69},{"id":81,"disease":56,"label":82,"population":85,"type":90,"unit":29,"dose":91,"refs":94,"allowedFormulations":97,"notes":98},"child-lt40",{"fa":83,"en":84},"کودک ۶ ماه به بالا زیر ۴۰ kg — شروع ۰٫۰۵ mg\u002Fkg دو بار در روز (محلول)","Child ≥6 months, \u003C40 kg — start 0.05 mg\u002Fkg twice daily (solution)",{"minAge":86,"maxWeightKg":89},{"value":87,"unit":88},6,"month",39.99,"weightBased",{"perKgPerDose":92,"intervalHours":93},0.05,12,[95],{"source":34,"section":96},"2.2",[46],[99],{"text":100,"refs":103},{"fa":101,"en":102},"هر ۲ هفته ۰٫۰۵ mg\u002Fkg افزایش تا کاهش ضربان دست‌کم ۲۰٪. حداکثر: ۶ ماه تا ۱ سال ۰٫۲ mg\u002Fkg، ۱ سال به بالا ۰٫۳ mg\u002Fkg دو بار در روز (تا ۷٫۵ mg).","Increase by 0.05 mg\u002Fkg every 2 weeks to a ≥20% HR reduction. Max: 6 months–1 y 0.2 mg\u002Fkg, ≥1 y 0.3 mg\u002Fkg twice daily (up to 7.5 mg).",[104],{"source":34,"section":96},{"id":106,"disease":56,"label":107,"population":110,"type":64,"unit":29,"dose":114,"refs":116,"allowedFormulations":118},"child-40plus",{"fa":108,"en":109},"کودک ۴۰ kg و بیشتر — شروع ۲٫۵ mg دو بار در روز","Child ≥40 kg — start 2.5 mg twice daily",{"minAge":111,"maxAge":112,"minWeightKg":113},{"value":87,"unit":88},{"value":62,"unit":63},40,{"perDose":115,"dosesPerDay":66},2.5,[117],{"source":34,"section":96},[23],[120],{"id":121,"severity":122,"text":123,"refs":126},"ci","block",{"fa":124,"en":125},"نارسایی حاد جبران‌نشده قلب؛ افت فشار مهم؛ سندرم سینوس بیمار، بلوک SA یا AV درجه ۳ بدون پیس‌میکر؛ برادی‌کاردی مهم؛ نارسایی شدید کبد؛ وابستگی به پیس‌میکر؛ مهارکننده‌های قوی CYP3A4.","Acute decompensated HF; significant hypotension; sick sinus, SA block or 3rd-degree AV block without pacemaker; significant bradycardia; severe hepatic impairment; pacemaker dependence; strong CYP3A4 inhibitors.",[127],{"source":34,"section":128},"4",[],[],[],[],{"status":134,"reviewer":135,"date":135},"unverified",null,[137,142,146],{"regimen":55,"formulation":23,"input":138,"expect":141},{"ageYears":139,"weightKg":140},60,75,{"perDose":28,"tabletsPerDoseRounded":5},{"regimen":81,"formulation":46,"input":143,"expect":145},{"ageYears":87,"weightKg":144},20,{"perDose":5,"mlPerDose":5},{"regimen":106,"formulation":23,"input":147,"expect":150},{"ageYears":148,"weightKg":149},14,45,{"perDose":115,"tabletsPerDoseRounded":151},0.5,[153],"C01EB17",{"status":155,"forms":156,"refs":165},"registered",[157,161],{"code":158,"en":159,"fa":160},"17011","IVABRADINE 5MG TAB","قرص ایوابرادین ۵ میلی‌گرم",{"code":162,"en":163,"fa":164},"52101","IVABRADINE 7.5MG TAB","قرص ایوابرادین ۷٫۵ میلی‌گرم",[166],{"source":167,"section":168,"url":169},"darooyab-generic","G-4766\u002FIvabradine","https:\u002F\u002Fwww.darooyab.ir\u002FG-4766\u002FIvabradine",[171,175,179,182,185],{"kind":172,"url":173,"label":174},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=206143","NDA206143",{"kind":176,"url":177,"label":178},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=92018a65-38f6-45f7-91d4-a34921b81d0d","FDA Corlanor",{"kind":180,"url":181,"label":8},"medlineplus","https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa615027.html",{"kind":183,"url":184,"label":153},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=C01EB17",{"kind":186,"url":169,"label":8},"darooyab",{"pregnancy":188,"lactation":197,"pediatric":205,"geriatric":214,"reproductive":222},{"level":189,"text":190,"quote":193,"refs":194},"avoid",{"fa":191,"en":192},"برچسب: می‌تواند به جنین آسیب بزند. در بارداری خطرناک است.","Label: can cause fetal harm. Dangerous in pregnancy.","Risk Summary Based on findings in animals, Corlanor may cause fetal harm when administered to a pregnant woman.",[195],{"source":34,"section":196},"8.1",{"level":189,"text":198,"quote":201,"refs":202},{"fa":199,"en":200},"برچسب: شیردهی توصیه نمی‌شود یا باید بین دارو و شیردهی یکی انتخاب شود.","Label: breastfeeding not recommended, or choose between the drug and breastfeeding.","Because of the potential risk to breastfed infants from exposure to Corlanor, breastfeeding is not recommended.",[203],{"source":34,"section":204},"8.2",{"level":206,"text":207,"quote":210,"refs":211},"caution",{"fa":208,"en":209},"برچسب برای کودکان شرط، محدودیت سنی یا نکته دارد؛ جمله برچسب در زیر آمده است.","The label has conditions, age limits or notes for children; the label sentence is quoted below.","The safety and effectiveness of Corlanor have been established in pediatric patients (age 6 months to less than 18 years old) and are supported by pharmacokinetic and pharmacodynamic trials and evidence from adequate and well-controlled trials of Corlanor in adult patients.",[212],{"source":34,"section":213},"8.4",{"level":206,"text":215,"quote":218,"refs":219},{"fa":216,"en":217},"برچسب: در سالمندان با احتیاط و معمولاً از دوز پایین شروع شود.","Label: use with caution in older adults, usually starting at the low end of the dose range.","No pharmacokinetic differences have been observed in elderly (≥ 65 years) or very elderly (≥ 75 years) patients compared to the overall population.",[220],{"source":34,"section":221},"8.5",{"level":206,"text":223,"quote":226,"refs":227},{"fa":224,"en":225},"برچسب نکته‌ای درباره بارداری، پیشگیری یا باروری زنان و مردان دارد.","Label has advice on pregnancy testing, contraception or fertility for females and males.","Contraception Females Corlanor may cause fetal harm, based on animal data.",[228],{"source":34,"section":229},"8.3",{"kind":231,"refs":232,"id":174},"NDA",[233],{"source":34,"section":234},"SPL approval \u002F marketing category",1792111457885]